Please ensure Javascript is enabled for purposes of website accessibility

If You Invested $5,000 in Dexcom During the Coronavirus Market Crash, This Is How Much Money You'd Have Now

By Rachel Warren – Sep 17, 2020 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The growth stock is outpacing the S&P 500 thanks to its foothold in the market for diabetes management.

The March market crash and volatility that's followed have revealed the stocks that are recession-proof champions, while pulling back the curtain on companies far more vulnerable to economic adversity. Among healthcare companies that have continued to achieve profitable returns, Dexcom (DXCM -0.81%) is top-of-mind. The company is known for manufacturing and marketing continuous glucose monitoring (CGM) devices.

Dexcom has consistently surpassed the S&P 500's performance this year, experiencing substantial and relatively consistent gains during a roller-coaster year. As of Sept. 16, Dexcom has gained 82% year-to-date compared to the S&P 500's return of about 5.5%.

If you're curious about what a $5,000 investment in Dexcom back in March would be worth today, you've come to the right place. Let's dig deeper into Dexcom's performance over the past six months. 

young man tossing money into the air and smiling for joy

Image source: Getty Images.

$5,000 would be worth...

Shares of Dexcom dipped only moderately in the March market crash. The stock closed at $219.38 on Jan. 2., the first trading day of the year. Shares hit their lowest point on March 17, when Dexcom closed at $191.16, down about 13% from the start of 2020. The stock started to recover at the end of March and has risen with momentum ever since.

Let's suppose that you invested in Dexcom on March 17, when the stock hit its low. With $5,000 to spend, you would have been able to purchase around 26 shares of the company. Today, that investment would be worth over $10,200. Not many stocks give you the opportunity to more than double your money in just six months.

The explanation for Dexcom's resilience in the face of extreme market headwinds isn't all that complicated. The company is a prominent manufacturer of CGM devices, which are in considerable demand despite adverse market conditions and serve a huge population of healthcare consumers. It's been estimated that roughly 34.2 million people, or about 11% of the entire American population, has diabetes. The CGM market is projected to realize a compound annual growth rate (CAGR) of more than 12% between 2020 and 2026. Diabetes patients are also among those most at risk of suffering serious complications from COVID-19, which has only heightened demand for Dexcom's products since the pandemic began.  

DXCM Chart

DXCM data by YCharts

A key leader in the continuous glucose monitoring device market 

Dexcom's star product is its G6 system, a one-touch applicator that generates blood glucose levels in real-time. The company recently concluded the launch of its G6 Pro system, marketed as "the first and only single-use, professional CGM available in blinded and unblinded modes." In blinded mode, patients won't have access to their glucose readings, alarms, or other G6 app health alerts. This setting allows care providers to capture patients' health information while they are behaving normally, without the influence of a CGM. Unblinded mode allows patients full access to their glucose levels and other tracked information on the Dexcom G6 app. 

Dexcom grew its first quarter revenue by 44% and recent second quarter revenue by 34% year over year.  In the second quarter, which ended on June 30, Dexcom saw 38% domestic revenue growth and 21% revenue growth in markets outside the U.S. The company also reported gross profit margins on the basis of generally accepted accounting principles (GAAP) of more than 63% in Q1 and 62.9% in Q2. 

Management expects the company to increase its annual revenue by 25% compared to 2019, achieving total revenues of $1.9 billion and a gross profit margin of 65% or greater for the full year. As of June 30, Dexcom reported cash and marketable securities equivalent to $2.5 billion, which positively outweighs its total liabilities of $2.2 billion. Currently, the company doesn't pay a dividend, which frees up a considerable portion of its cash reserves to work on paying off existing debt.

Should you take the plunge? 

Analysts are optimistic about Dexcom's growth trajectory over the next few years. They project that the company will boost its earnings by more than 55% per year through 2025. In fact, Dexcom was popular with investors for its consistent earnings growth before the pandemic, and has continued its streak in the worst economic recession since the Great Depression.

The company has consistently grown its annual earnings by double digits over the past five years alone: 2015 (55%), 2016 (43%), 2017 (25%), 2018 (44%), and 2019 (43%). Dexcom's stellar balance sheet and excellent cash-to-debt ratio also set the company up for success, and its addressable market for diabetes management in the U.S. and abroad is poised for continued growth. For all of these reasons, I believe that investors should scoop up shares of the growth stock now, before it soars even higher. 

Rachel Warren has no position in any of the stocks mentioned. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom Stock Quote
DexCom
DXCM
$112.00 (-0.81%) $0.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.